Alumis Inc. (ALMS)

NMS – Цена в реальном времени. Валюта: USD

23.51

-0.15 (-0.63%)

При закрытии: May 12, 2026, 4:00 PM EDT

23.00

-0.51 (-2.17%)

После закрытия: May 12, 2026, 6:59 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Alumis Inc. (ALMS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alumis Inc. (ALMS)

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis to Participate in Upcoming February Investor Conferences

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Видео

No Data

Пресс-релизы

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Search stocks

Alumis Inc. (ALMS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Alumis Inc. (ALMS)

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis to Participate in Upcoming February Investor Conferences

Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.

Видео

No Data

Пресс-релизы

Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares